DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,998,587 | -51.8% | 36,270 | -53.4% | 0.09% | -42.1% |
| Q2 2023 | $18,678,480 | +123.6% | 77,827 | +134.8% | 0.15% | +11.8% |
| Q1 2023 | $8,354,118 | -88.4% | 33,146 | -87.8% | 0.14% | -72.0% |
| Q4 2022 | $72,200,876 | +2713.8% | 272,025 | +2638.3% | 0.49% | +1250.0% |
| Q3 2022 | $2,566,000 | -77.6% | 9,934 | -78.0% | 0.04% | -66.7% |
| Q2 2022 | $11,453,000 | -70.2% | 45,174 | -65.5% | 0.11% | -64.0% |
| Q1 2022 | $38,400,000 | -70.1% | 130,912 | -66.5% | 0.30% | -56.1% |
| Q4 2021 | $128,582,000 | +194.6% | 390,814 | +172.6% | 0.68% | +130.3% |
| Q3 2021 | $43,646,000 | +269.0% | 143,366 | +225.3% | 0.30% | +262.2% |
| Q2 2021 | $11,829,000 | -13.0% | 44,077 | -27.1% | 0.08% | -3.5% |
| Q1 2021 | $13,601,000 | -47.4% | 60,428 | -48.1% | 0.08% | -34.6% |
| Q4 2020 | $25,878,000 | +58.0% | 116,496 | +53.2% | 0.13% | -18.8% |
| Q3 2020 | $16,374,000 | +49.9% | 76,041 | +23.1% | 0.16% | +36.8% |
| Q2 2020 | $10,922,000 | -20.2% | 61,767 | -37.5% | 0.12% | -33.1% |
| Q1 2020 | $13,687,000 | +18.0% | 98,886 | +30.8% | 0.18% | +133.3% |
| Q4 2019 | $11,603,000 | -65.2% | 75,599 | -67.2% | 0.08% | -75.9% |
| Q3 2019 | $33,311,000 | +12.0% | 230,641 | +10.8% | 0.31% | +35.8% |
| Q2 2019 | $29,740,000 | +48.8% | 208,087 | +37.5% | 0.23% | +40.5% |
| Q1 2019 | $19,984,000 | -51.6% | 151,369 | -62.2% | 0.16% | -15.1% |
| Q4 2018 | $41,256,000 | +123.0% | 400,086 | +135.0% | 0.19% | +21.5% |
| Q3 2018 | $18,501,000 | -70.8% | 170,269 | -73.5% | 0.16% | -71.1% |
| Q2 2018 | $63,304,000 | +468.2% | 641,512 | +463.8% | 0.55% | +362.7% |
| Q1 2018 | $11,141,000 | -11.9% | 113,788 | -16.5% | 0.12% | +29.7% |
| Q4 2017 | $12,648,000 | +56.9% | 136,266 | +45.0% | 0.09% | +18.2% |
| Q3 2017 | $8,060,000 | -68.2% | 93,959 | -68.8% | 0.08% | -71.4% |
| Q2 2017 | $25,385,000 | +27.0% | 300,808 | +28.7% | 0.27% | +66.0% |
| Q1 2017 | $19,991,000 | -27.0% | 233,733 | -33.6% | 0.16% | -42.1% |
| Q4 2016 | $27,384,000 | +148.3% | 351,797 | +150.1% | 0.28% | +33.3% |
| Q3 2016 | $11,027,000 | -1.3% | 140,668 | +17.0% | 0.21% | -7.5% |
| Q4 2015 | $11,167,000 | – | 120,233 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |